8-K: Philip Morris International Reports Strong Q1 2024 Results, Raises Full-Year Guidance

Philip Morris International announced a strong first quarter in 2024, with significant growth in smoke-free products and an increase in adjusted diluted EPS, leading to an improved full-year outlook.

Summary

• Philip Morris International (PMI) reported its first-quarter 2024 results, showing a 7.8% increase in reported diluted EPS to $1.38 and an 8.7% increase in adjusted diluted EPS to $1.50.
• Excluding currency impacts, adjusted diluted EPS grew by 23.2% to $1.70.
• The company's smoke-free business (SFB) now accounts for 39% of total net revenues, with significant growth in the EA, AU & PMI DF region, where SFB makes up almost two-thirds of revenue.
• SFB net revenues increased by 21.1% (24.8% organically), and gross profit increased by 31.8% (37.5% organically).
• IQOS continues to strengthen its position, becoming the second-largest nicotine brand in markets where it is present and holding the number one position in 11 markets.
• Adjusted in-market sales (IMS) volume for heated tobacco units (HTUs) increased by an estimated 12.5%.
• In Europe, IQOS HTU market share exceeded 10% for the first time, with adjusted IMS growth of 9.4%.
• In Japan, IQOS HTU market share increased by more than 3 percentage points to over 29%, with adjusted IMS growth of 13.3%.
• Oral SFP shipment volume increased by 40.0% in cans (35.8% in pouches or pouch equivalents), driven by ZYN nicotine pouch growth in the U.S., where shipment volume reached 131.6 million cans, a 79.7% increase year-over-year.
• Combustibles net revenues grew by 3.5% (3.7% organically), with Marlboro gaining 0.4 percentage points in category share.
• PMI declared a regular quarterly dividend of $1.30 per share, or an annualized rate of $5.20 per share.
• The company has raised its 2024 currency-neutral guidance, projecting adjusted diluted EPS of $6.55-$6.67, a 9.0%-11.0% increase compared to 2023.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with strong growth in key areas, particularly smoke-free products, and an increase in full-year guidance. While there are some challenges, the overall tone is optimistic and indicates a strong financial performance.

Positives

• Strong growth in smoke-free products, particularly IQOS and ZYN, is driving revenue and profit increases.
• The company is successfully expanding its smoke-free business in key markets like Japan and Europe.
• PMI is demonstrating strong pricing power in the combustibles market.
• The company is effectively managing costs and mitigating currency headwinds.
• The increase in full-year guidance indicates confidence in future performance.
• The company is seeing strong growth in the US market with ZYN nicotine pouches.
• The company is improving its net debt to adjusted EBITDA ratio.

Negatives

• The company experienced a $0.20 unfavorable currency variance in the first quarter, including a $0.09 impact from the devaluation of the Egyptian pound.
• There was a decline in cigarette shipment volumes across most regions.
• The company recorded pre-tax asset impairment and exit costs of $121 million related to restructuring the sourcing of IQOS products in the U.S.
• The company ceased operations in Venezuela, resulting in pre-tax asset impairment and exit costs of $47 million.
• The company is facing an approximate 2 billion unit adverse impact for the full year from consumer adjustment to the EU characterizing flavor ban.

Risks

• The company faces risks related to excise tax increases, regulatory restrictions, and health concerns related to tobacco and nicotine use.
• PMI is exposed to litigation risks related to tobacco and intellectual property.
• The company is subject to intense competition and the effects of global economic, regulatory, and political developments.
• Unfavorable currency exchange rates and currency devaluations pose a risk to profitability.
• The company's future profitability may be adversely affected if it is unsuccessful in its attempts to grow smoke-free products.
• The company is subject to risks related to the cost, availability, and quality of tobacco and other raw materials.
• The company is subject to risks related to the integrity of its information systems and effectiveness of its data privacy policies.

Future Outlook

PMI has raised its full-year 2024 guidance, projecting adjusted diluted EPS of $6.55-$6.67, a 9.0%-11.0% increase compared to 2023, excluding currency impacts. The company expects continued growth in smoke-free products and aims to improve its net debt to adjusted EBITDA ratio to around 2x by the end of 2026. No share repurchases are planned for 2024.

Management Comments

• The strength of our first-quarter results with excellent top-line growth and significant margin expansion gives us the confidence to raise our 2024 currency-neutral guidance, said Jacek Olczak, Chief Executive Officer.
• Strong smoke-free momentum continues with rapid underlying volume progression and accelerating organic net revenue and gross profit growth, fueled by the operating leverage of IQOS and the best-in-class economics of ZYN.
• We are executing efficiently and effectively in a dynamic operating environment of geopolitical and economic tensions that accentuate currency volatility. We are doing our utmost to mitigate these challenges and deliver robust growth and value creation.

Industry Context

The results reflect a broader industry trend of shifting away from traditional combustible tobacco products towards smoke-free alternatives. PMI's strong performance in the smoke-free category, particularly with IQOS and ZYN, positions it well in this evolving market. The company's focus on innovation and scientific substantiation of its smoke-free products aligns with increasing regulatory and consumer demand for less harmful alternatives.

Comparison to Industry Standards

• PMI's 24.8% organic growth in smoke-free net revenue significantly outpaces the growth of traditional tobacco companies, such as British American Tobacco (BAT) and Imperial Brands, which are also transitioning to smoke-free products but at a slower pace.
• The 12.5% growth in HTU adjusted in-market sales volume demonstrates PMI's leadership in the heated tobacco category, where competitors like Japan Tobacco (JT) are also present but with less market share in key regions.
• PMI's ZYN nicotine pouch growth in the U.S. is a strong indicator of its success in the oral nicotine category, where it competes with companies like Swedish Match (now part of PMI) and Altria, but with a larger market share.
• The company's adjusted operating income margin of 38.2% is competitive with industry leaders, reflecting its ability to manage costs and generate profits from its diverse product portfolio.
• The company's focus on scientific substantiation and regulatory approvals for its smoke-free products sets it apart from some competitors who may face challenges in meeting stringent regulatory requirements.

Stakeholder Impact

• Shareholders will benefit from the increased dividend and positive financial outlook.
• Employees may see increased job security and opportunities due to the company's growth.
• Customers will have access to a wider range of smoke-free products.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower risk due to its improved financial performance.

Next Steps

• The company will continue to focus on growing its smoke-free business and expanding its market share.
• PMI will continue to invest in research and development of innovative smoke-free products.
• The company will work to mitigate currency headwinds and manage costs effectively.
• PMI will continue to monitor and adapt to regulatory changes and market dynamics.

Key Dates

Keywords

Philip Morris International, PMI, IQOS, ZYN, Smoke-free products, Heated tobacco units, HTU, Nicotine pouches, Combustibles, Earnings, EPS, Financial results, Dividend, Guidance